In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 857-859

  Niki, Yoshihito ^a   Miyashita, Naoyuki ^a   Kubota, Yoshifumi ^a   Nakajima, Masamitsu ^a   Matsushima, Toshiharu ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; MINOCYCLINE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SURVIVAL;

EID: 0030980616     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.857     Document Type: Article

References (10)

1. Grayston, J. T., S. P. Wang, C. C. Kuo, and L. A. Campbell. 1989. Current knowledge on Chlamydia pneumoniae strain, TWAR, an important cause of pneumonia and other acute respiratory diseases. Eur. J. Clin. Microbiol. Infect. Dis. 8:191-202.
2. Hammerschlag, M. R., C. L. Hyman, and R. M. Robin. 1992. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:682-683.
3. Japan Society of Chemotherapy. 1989. Method for in vitro determination of chlamydial susceptibility (minimum inhibitory concentration; MIC) to antimicrobial agents - standard method of Japan Society of Chemotherapy. Chemotherapy (Tokyo) 37:1308-1313.
4. Kauppinen, M. T., E. Herva, P. Kajala, M. Leinonen, P. Saikku, and H. Syvjälä. 1995. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J. Infect. Dis. 172:1330-1335.
5. Kimura, M., T. Kishimoto, Y. Niki, and R. Soejima. 1993. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob. Agents Chemother. 37:801-803.
6. Kubota, Y., Y. Niki, M. Nakajima, R. Soejima, and K. Nakata. 1995. In vitro and in vivo activities of newly developed fluoroquinolones against chlamydia. Jpn. J. Chemother. (Tokyo) 43:520-524.
7. Niki, Y., M. Kimura, N. Miyashita, and R. Soejima. 1994. In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. Antimicrob. Agents Chemother. 38:2296-2299.
8. Okezaki, E., Y. Watanabe, T. Hirose, T. Yoshida, Y. Aoki, and H. Kato. 1995. Antibacterial activity of HSR-903, a new novel quianolone, abstr. F202, p. 148. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Soejima, R., Y. Niki, T. Kishimoto, N. Miyashita, Y. Kubota, and K. Nakata. 1995. In vitro and in vivo activities of sparfloxacin and reference drugs against Chlamydia pneumoniae. J. Infect. Chemother. (Tokyo) 1:89-152.
10. Soejima, R., Y. Niki, N. Okimoto, T. Kishimoto, and Japan Sparfloxacin Respiratory Chlamydial Infection Study Group. 1996. Clinical study on sparfloxacin in the treatment of chlamydial respiratory infections. Jpn. J. Chemother. (Tokyo) 44:148-159.